Atara Biotherapeutics (NASDAQ:ATRA) Upgraded to “Hold” at Wall Street Zen
by Doug Wharley · The Cerbat GemWall Street Zen upgraded shares of Atara Biotherapeutics (NASDAQ:ATRA – Free Report) from a sell rating to a hold rating in a report released on Sunday.
Other equities research analysts have also issued research reports about the company. Freedom Capital raised Atara Biotherapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, May 18th. Canaccord Genuity Group set a $13.00 price objective on Atara Biotherapeutics and gave the company a “buy” rating in a research report on Friday, May 8th. Finally, Weiss Ratings downgraded shares of Atara Biotherapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, July 31st. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $9.50.
Read Our Latest Stock Analysis on Atara Biotherapeutics
Atara Biotherapeutics Price Performance
NASDAQ:ATRA opened at $8.09 on Friday. The company has a market capitalization of $72.89 million, a PE ratio of -6.86 and a beta of 0.12. Atara Biotherapeutics has a 52-week low of $3.92 and a 52-week high of $19.15. The stock has a fifty day simple moving average of $9.40 and a 200-day simple moving average of $7.31.
Atara Biotherapeutics (NASDAQ:ATRA – Get Free Report) last issued its quarterly earnings data on Wednesday, August 12th. The biotechnology company reported ($0.32) EPS for the quarter, meeting analysts’ consensus estimates of ($0.32). The firm had revenue of $0.63 million for the quarter, compared to analysts’ expectations of $0.55 million. Atara Biotherapeutics had a negative net margin of 269.42% and a negative return on equity of 79.12%. As a group, equities analysts anticipate that Atara Biotherapeutics will post -0.16 earnings per share for the current year.
Institutional Inflows and Outflows
Several large investors have recently modified their holdings of the stock. Raymond James Financial Inc. purchased a new stake in shares of Atara Biotherapeutics during the 2nd quarter valued at $31,000. Dimensional Fund Advisors LP acquired a new stake in Atara Biotherapeutics during the fourth quarter worth about $181,000. Walleye Capital LLC purchased a new position in shares of Atara Biotherapeutics in the 4th quarter worth about $220,000. Marshall Wace LLP purchased a new position in shares of Atara Biotherapeutics in the 2nd quarter worth about $327,000. Finally, Quadrature Capital Ltd lifted its stake in shares of Atara Biotherapeutics by 22.8% in the 4th quarter. Quadrature Capital Ltd now owns 20,321 shares of the biotechnology company’s stock valued at $368,000 after purchasing an additional 3,779 shares in the last quarter. 70.90% of the stock is currently owned by hedge funds and other institutional investors.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc is a biotechnology company focused on the discovery, development and commercialization of novel T-cell immunotherapies to transform the treatment of cancer and autoimmune disease. Headquartered in South San Francisco, California, Atara leverages its proprietary off-the-shelf allogeneic Epstein-Barr virus (EBV)-directed T-cell platform to generate engineered cell therapies designed to target EBV-driven malignancies and immune-mediated disorders.
The company’s lead product candidate, tabelecleucel, is an off-the-shelf, EBV-specific T-cell therapy in clinical development for the treatment of EBV-positive post-transplant lymphoproliferative disease (PTLD) and other EBV-associated cancers.